JP2021533770A5 - - Google Patents

Info

Publication number
JP2021533770A5
JP2021533770A5 JP2021507628A JP2021507628A JP2021533770A5 JP 2021533770 A5 JP2021533770 A5 JP 2021533770A5 JP 2021507628 A JP2021507628 A JP 2021507628A JP 2021507628 A JP2021507628 A JP 2021507628A JP 2021533770 A5 JP2021533770 A5 JP 2021533770A5
Authority
JP
Japan
Prior art keywords
antibody
seq
antigen
chain variable
variable region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021507628A
Other languages
English (en)
Japanese (ja)
Other versions
JP7576022B2 (ja
JP2021533770A (ja
Filing date
Publication date
Priority claimed from CN201810920403.6A external-priority patent/CN110818793A/zh
Application filed filed Critical
Publication of JP2021533770A publication Critical patent/JP2021533770A/ja
Publication of JP2021533770A5 publication Critical patent/JP2021533770A5/ja
Application granted granted Critical
Publication of JP7576022B2 publication Critical patent/JP7576022B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021507628A 2018-08-14 2019-08-13 抗IL-1β抗体およびその医薬組成物およびそれらの使用 Active JP7576022B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201810920403.6A CN110818793A (zh) 2018-08-14 2018-08-14 抗IL-1β的抗体、其药物组合物及其用途
CN201810920403.6 2018-08-14
PCT/CN2019/100343 WO2020034941A1 (zh) 2018-08-14 2019-08-13 抗IL-1β的抗体、其药物组合物及其用途

Publications (3)

Publication Number Publication Date
JP2021533770A JP2021533770A (ja) 2021-12-09
JP2021533770A5 true JP2021533770A5 (cg-RX-API-DMAC7.html) 2022-08-09
JP7576022B2 JP7576022B2 (ja) 2024-10-30

Family

ID=69524699

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021507628A Active JP7576022B2 (ja) 2018-08-14 2019-08-13 抗IL-1β抗体およびその医薬組成物およびそれらの使用

Country Status (15)

Country Link
US (2) US12286473B2 (cg-RX-API-DMAC7.html)
EP (1) EP3845560A4 (cg-RX-API-DMAC7.html)
JP (1) JP7576022B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210046024A (cg-RX-API-DMAC7.html)
CN (2) CN110818793A (cg-RX-API-DMAC7.html)
AU (1) AU2019320927B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021002794A2 (cg-RX-API-DMAC7.html)
CA (1) CA3108414A1 (cg-RX-API-DMAC7.html)
EA (1) EA202190518A1 (cg-RX-API-DMAC7.html)
IL (1) IL280596B2 (cg-RX-API-DMAC7.html)
MX (2) MX2021001778A (cg-RX-API-DMAC7.html)
MY (1) MY209465A (cg-RX-API-DMAC7.html)
PH (1) PH12021550298A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202101435XA (cg-RX-API-DMAC7.html)
WO (1) WO2020034941A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110818793A (zh) * 2018-08-14 2020-02-21 中山康方生物医药有限公司 抗IL-1β的抗体、其药物组合物及其用途
CN113444177A (zh) * 2020-03-27 2021-09-28 中山康方生物医药有限公司 抗IL-1β的抗体、其药物组合物及其用途
BR112022022089A2 (pt) * 2020-05-22 2022-12-13 R Pharm Overseas Inc Composição de proteína heterodimérica, composição terapêutica que compreende a mesma e uso da dita composição para tratar uma doença associada à modulação de il-1ss
US20230220065A1 (en) * 2020-06-16 2023-07-13 Academia Sinica Antibodies to interleukin-1beta and uses thereof
CN116063488B (zh) * 2022-10-21 2025-09-30 杭州靶向食品科技有限公司 一种单克隆抗体及其治疗痛风的用途
CN116688130A (zh) * 2023-06-08 2023-09-05 桂林医学院附属医院 靶向IL-1β/IL-1R1通路的拮抗剂在抑制肝癌肺转移前微环境或肺转移的药物中的应用
KR102844307B1 (ko) 2023-09-26 2025-08-07 사회복지법인 삼성생명공익재단 비흡연자의 조기 폐암 진단용 바이오마커 및 이의 용도

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
GB0001448D0 (en) 2000-01-21 2000-03-08 Novartis Ag Organic compounds
GB0020685D0 (en) 2000-08-22 2000-10-11 Novartis Ag Organic compounds
MXPA05002514A (es) * 2002-09-06 2005-05-27 Amgen Inc Anticuerpo monoclonal anti-il-1r1 humano terapeutico.
JP4538461B2 (ja) 2003-01-24 2010-09-08 アプライド モレキュラー エボリューション,インコーポレイテッド ヒトIL−1βアンタゴニスト
GB0303337D0 (en) * 2003-02-13 2003-03-19 Celltech R&D Ltd Biological products
US20050100965A1 (en) * 2003-11-12 2005-05-12 Tariq Ghayur IL-18 binding proteins
ES2335232T3 (es) * 2005-06-21 2010-03-23 Xoma Technology Ltd. Anticuerpos y fragmentos de los mismos que se unen a la il-1 beta.
WO2008145664A1 (en) 2007-05-29 2008-12-04 Novartis Ag New indications for anti- il-i-beta therapy
AU2010306681A1 (en) * 2009-10-15 2012-04-19 Abbvie Inc. IL-1 binding proteins
WO2012034039A2 (en) * 2010-09-10 2012-03-15 Apexigen, Inc. Anti-il-1 beta antibodies and methods of use
KR102049223B1 (ko) * 2010-11-04 2019-11-28 베링거 인겔하임 인터내셔날 게엠베하 항-il-23 항체
RU2563830C2 (ru) * 2011-02-08 2015-09-20 Эббви Инк. Лечение остеоартрита и боли
MX374817B (es) * 2012-11-05 2025-03-06 Delenex Therapeutics Ag Miembros de union para il-1 beta.
AU2014227732A1 (en) * 2013-03-15 2015-09-17 Abbvie Inc. Dual specific binding proteins directed against IL-1 beta and IL-17
CN103554264B (zh) * 2013-11-05 2015-08-12 哈尔滨博翱生物医药技术开发有限公司 针对IL-1β和IL-17A的双特异性抗体及其应用
JP2017537896A (ja) * 2014-11-10 2017-12-21 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 二重特異性抗体及び眼科に使用する方法
SG11201702550WA (en) * 2014-11-10 2017-04-27 Hoffmann La Roche ANTI-IL-1beta ANTIBODIES AND METHODS OF USE
CN107474139B (zh) * 2017-06-23 2021-04-27 苏州博聚华生物医药科技有限公司 一种靶向人肿瘤干细胞的单克隆抗体及其应用
CN110818793A (zh) * 2018-08-14 2020-02-21 中山康方生物医药有限公司 抗IL-1β的抗体、其药物组合物及其用途
CN113444177A (zh) 2020-03-27 2021-09-28 中山康方生物医药有限公司 抗IL-1β的抗体、其药物组合物及其用途

Similar Documents

Publication Publication Date Title
JP7273101B2 (ja) Cd38に結合する抗体治療剤
CN108290948B (zh) 抗-cd47抗体及使用方法
JP7575102B2 (ja) Muc18に特異的な抗体
CN112969714B (zh) 抗cd40抗体、其抗原结合片段及其医药用途
JP7257971B2 (ja) 抗cd40抗体、その抗原結合フラグメント、およびその医学的使用
KR20180006369A (ko) Cd47에 결합하는 항체 치료제
TWI797609B (zh) 抗pd-1和pd-l1的四價雙特異性抗體
CN114729053B (zh) 一种4-1bb结合蛋白及其应用
CN114981301B (zh) Pd1和vegfr2双结合剂
CN115785268B (zh) 抗cd47抗体及其用途
JP7578289B2 (ja) Muc18に特異的な抗体
US11680102B2 (en) Anti-BAFF receptor antibodies and uses thereof
KR20150063311A (ko) Il-6 결합 분자
CA3108414A1 (en) Antibody against il-1.beta., pharmaceutical composition and use thereof
KR20240135654A (ko) 항-her2/trop2 항체 및 이의 용도
JP2024533457A5 (cg-RX-API-DMAC7.html)
KR20220119389A (ko) 분리된 항원 axl 결합 단백질 및 그의 용도
KR20250067124A (ko) 이중특이성 항-c-kit 및 항-cd203c 항원 결합 분자 및 이의 용도
KR20220110753A (ko) 항-bcma/항-4-1bb 이중특이성 항체 및 그의 용도
JP7036471B2 (ja) デスレセプター4及びデスレセプター5に結合する非常に強力な抗体
CA3221903A1 (en) Anti-upar antibodies and uses thereof
AU2019388931A1 (en) CD40 antibody pharmaceutical composition and use thereof
KR20240123800A (ko) 항tnfr2 항체 및 이의 용도
CN111303288B (zh) 一种分离的结合抗原psma的蛋白及其用途
TH2101000822A (th) แอนติบอดีสารต้าน lL-1เบตา และองค์ประกอบเชิงเภสัชกรรมของสิ่งเหล่านั้นและการใช้ของสิ่งเดียวกันนั้น